Skip to main content
Premium Trial:

Request an Annual Quote

David Onions, V.W. Brinkerhoff, Joshua Boger, Joseph Scodari, Andrew Baum, Mark Skaletsky, Salvatore Salamone, James Pusey

BioReliance has appointed David Onions its chief scientific officer, effective June 18. Onions will run the company’s global clinical and preclinical scientific activities, the company said. Onions comes to BioReliance from Invitrogen, where he was chief medical officer.

Gene Logic has promoted V.W. Brinkerhoff to the post of senior vice president of administration. He will receive a $100,000 cash incentive bonus and a $250,000 executive cash incentive target for 2007.
Brinkerhoff joined Gene Logic in 2005 as senior vice president and general manager for its preclinical contract research business. Prior to joining Gene Logic, he was group vice president for operations at Wilson Greatbatch Technologies. Earlier, he held senior management positions with Life Technologies, which Invitrogen acquired in 2000.

The Biotechnology Industry Organization elected new board members last week in conjunction with its annual international convention:  
  • Joshua Boger, chairman, president, and CEO of Vertex Pharmaceuticals, was elected chairman of the board. He succeeds James Mullen, CEO of Biogen;  
  • Joseph Scodari, worldwide chairman of Johnson & Johnson’s Pharmaceuticals group, was named vice chair of healthcare; 
  • Andrew Baum of SemBioSys Genetics was appointed vice chair of food and agriculture, and secretary; and  
  • Mark Skaletsky, chairman, president, and CEO of Trine Pharmaceuticals, was named treasurer.  

US Genomics has named Salvatore Salamone to its board of directors. Salamone is chairman and CEO of Saladax Biomedical. He formerly was vice president of R&D at Roche Diagnostics and was senior vice president of R&D at Orasure Technologies.

MDS Pharma Services has hired James Pusey as vice president and general manager of its global clinical-development business.

Pusey formerly was president and CEO of OrthoLogic, executive vice president for neurology at Serono, and vice president of marketing and therapeutics area leader for AstraZeneca.

Filed under

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.